NCT04167137 - Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

December 9, 2021

Study Completion Date

December 9, 2021

Conditions

Metastatic Solid NeoplasmLymphoma

Interventions

DRUG

SYNB1891

SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.

DRUG

Atezolizumab

Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).

Trial Locations (6)

University of Pittsburgh Hillman Cancer Center, Pittsburgh

Ohio State University College of Medicine, Columbus

Mary Crowley Cancer Research, Dallas

University of Texas MD Anderson Cancer Center, Houston

University of Colorado School of Medicine, Aurora

Hackensack University John Theurer Cancer Center, Hackensack